Total Payments
$2,718
2024 Payments
$341.59
Companies
48
Transactions
145
Medicare Patients
1,528
Medicare Billing
$205,434
Payment Breakdown by Category
Food & Beverage$2,718 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,718 | 145 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $344.71 | 16 | $0 (2023) |
| Seagen Inc. | $170.21 | 10 | $0 (2023) |
| PFIZER INC. | $169.55 | 9 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $112.86 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $109.55 | 6 | $0 (2024) |
| Genentech USA, Inc. | $107.08 | 6 | $0 (2024) |
| GENZYME CORPORATION | $88.84 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $87.97 | 4 | $0 (2024) |
| Eisai Inc. | $72.58 | 4 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $68.41 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $341.59 | 17 | Novartis Pharmaceuticals Corporation ($44.74) |
| 2023 | $838.61 | 41 | E.R. Squibb & Sons, L.L.C. ($137.17) |
| 2022 | $764.49 | 43 | E.R. Squibb & Sons, L.L.C. ($133.07) |
| 2021 | $699.82 | 39 | E.R. Squibb & Sons, L.L.C. ($74.47) |
| 2020 | $31.22 | 2 | PFIZER INC. ($17.59) |
| 2018 | $16.15 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($16.15) |
| 2017 | $25.74 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($25.74) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.96 | General |
| Category: Hematology | ||||||
| 08/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.61 | General |
| Category: Oncology | ||||||
| 07/15/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $17.22 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 07/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Hematology | ||||||
| 06/17/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: IMMUNOLOGY | ||||||
| 05/21/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2024 | Heron Therapeutics, Inc. | CINVANTI (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: CHEMO INDUCED NAUSEA VOMITING | ||||||
| 04/22/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Oncology | ||||||
| 04/16/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Oncology | ||||||
| 04/08/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $25.94 | General |
| Category: Oncology | ||||||
| 04/01/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: Oncology | ||||||
| 03/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.88 | General |
| 03/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Immunology | ||||||
| 02/19/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: BioOncology | ||||||
| 02/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.15 | General |
| Category: ONCOLOGY | ||||||
| 01/08/2024 | PFIZER INC. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Oncology | ||||||
| 12/18/2023 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $18.07 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Hematology | ||||||
| 11/08/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.34 | General |
| Category: Oncology | ||||||
| 11/06/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Oncology | ||||||
| 10/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $29.12 | General |
| Category: Oncology | ||||||
| 10/09/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Oncology | ||||||
| 10/02/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Oncology | ||||||
| 09/25/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.70 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 636 | 23,884 | $122,205 | $68,670 |
| 2022 | 14 | 311 | 2,177 | $100,783 | $63,062 |
| 2021 | 18 | 407 | 9,971 | $93,092 | $58,779 |
| 2020 | 5 | 174 | 261 | $52,263 | $14,924 |
Total Patients
1,528
Total Services
36,293
Medicare Billing
$205,434
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 102 | 276 | $40,404 | $24,890 | 61.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 42 | 122 | $18,946 | $11,267 | 59.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 17 | 14,790 | $18,743 | $5,796 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $6,956 | $4,353 | 62.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 30 | $6,620 | $3,822 | 57.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 66 | $4,981 | $3,132 | 62.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 125 | $4,392 | $2,679 | 61.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $3,234 | $2,141 | 66.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 26 | 153 | $2,799 | $1,757 | 62.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 37 | $3,194 | $1,747 | 54.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 34 | 119 | $1,928 | $1,246 | 64.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 18 | $1,845 | $1,221 | 66.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 19 | $1,524 | $1,135 | 74.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 43 | $1,446 | $900.85 | 62.3% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 23 | 35 | $1,337 | $826.20 | 61.8% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 12 | 6,000 | $1,733 | $664.31 | 38.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 18 | 620 | $1,104 | $497.85 | 45.1% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 11 | 16 | $250.45 | $151.50 | 60.5% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 59 | 299 | $269.95 | $144.49 | 53.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 28 | 53 | $164.30 | $104.38 | 63.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 25 | 698 | $131.30 | $68.28 | 52.0% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 21 | 64 | $99.20 | $64.45 | 65.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 21 | 59 | $80.80 | $45.36 | 56.1% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 11 | 192 | $25.04 | $15.15 | 60.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 66 | 282 | $41,324 | $25,657 | 62.1% |
About Dr. James Schwarz, MD
Dr. James Schwarz, MD is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1710968847.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Schwarz, MD has received a total of $2,718 in payments from pharmaceutical and medical device companies, with $341.59 received in 2024. These payments were reported across 145 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($2,718).
As a Medicare-enrolled provider, Schwarz has provided services to 1,528 Medicare beneficiaries, totaling 36,293 services with total Medicare billing of $205,434. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Omaha, NE
- Active Since 11/07/2005
- Last Updated 10/23/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710968847
Products in Payments
- OPDIVO (Biological) $302.73
- IMBRUVICA (Drug) $112.86
- IBRANCE (Drug) $82.17
- ADCETRIS (Biological) $75.92
- TUKYSA (Drug) $73.32
- Lenvima (Drug) $72.58
- KEYTRUDA (Biological) $66.06
- SARCLISA (Biological) $61.86
- BLENREP (Biological) $53.33
- XALKORI (Drug) $52.14
- Epkinly (Drug) $51.57
- COSELA (Drug) $50.99
- XPOVIO (Drug) $49.00
- AYVAKIT (Drug) $47.23
- LIBTAYO (Biological) $45.03
- TIBSOVO (Drug) $43.76
- LUMAKRAS (Drug) $43.68
- Xermelo (Drug) $43.42
- Finacea (Drug) $41.89
- OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) $41.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Margaret Block, M.d, M.D
Hematology & Oncology — Payments: $444,214
Hematology & Oncology $444,214
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519